Physician profile
Antonio Rodriguez
NPI 1053300590
$5,402.31
in general payments reported to CMS, 2019-2025
25 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $320 · 2021: $1,102 · 2022: $387 · 2023: $807 · 2024: $405 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608 · Education: $34.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.60 |
| Education | $34.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,338.28 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $712.39 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Paratek Pharmaceuticals, INC. | $636.50 | 2021-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $536.56 | 2019-2023 | Ofev |
| La Jolla Pharmaceutical Company | $294.62 | 2021-2024 | Xacduro, Giapreza |
| Mylan Specialty L.P. | $246.51 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $225.53 | 2019 | |
| Philips North America LLC | $210.78 | 2019-2021 | |
| Genzyme Corporation | $205.99 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $152.97 | 2019 | |
| Abiomed | $148.44 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $135.34 | 2019-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $123.48 | 2022 | |
| Acacia Pharma INC | $83.98 | 2022 | |
| Grifols USA, LLC | $80.29 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $51.30 | 2025 | Brinsupri, Arikayce |
| Genentech USA, INC. | $43.24 | 2019 | |
| Baxter Healthcare | $27.77 | 2020 | |
| Portola Pharmaceuticals, LLC | $23.78 | 2020 | |
| Shire North American Group INC | $23.22 | 2019 | |
| Inspire Medical Systems, INC. | $22.63 | 2023 | Inspire |
| Pulmonx Corporation | $22.52 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Mallinckrodt Hospital Products INC. | $21.00 | 2021 | |
| Advanced Respiratory, INC | $20.57 | 2020 | |
| Pfizer INC. | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.